Overview

A Study to Assess the Safety and Efficacy of Intratumoral IMO-2125 in Combination With Ipilimumab or Pembrolizumab in Patients With Metastatic Melanoma

Status:
Completed

Trial end date:
2020-02-01

Target enrollment:

Participant gender:

Summary

The goal of this clinical research study is to find the recommended dose of the study drug IMO-2125 that can be given in combination with ipilimumab or in combination with pembrolizumab to patients with metastatic melanoma. Researchers also want to learn if the study drug combination can help to control the disease. The safety of the drug combination will also be studied.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Idera Pharmaceuticals, Inc.

Treatments:

Antibodies, Monoclonal
Ipilimumab
Pembrolizumab